LAS VEGAS--(BUSINESS WIRE)--March 28, 2006--Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today, it has new preclinical data gathered in a series of animal studies that shows its Cardiovascular drug SP-1000 reduces blood cholesterol.
